Delivery Order SPE2DB22D2103-SPE2DB25FR9UN
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 10 mg capsules (100-count units) under a firm fixed price contract on September 12, 2025, with a ceiling value of $1,337.70 and ultimate completion date of September 15, 2025. This non-competitive delivery order represents a continuation of AmerisourceBergen's role as a critical pharmaceutical vendor for federal medical procurement, leveraging the company's existing indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 13, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a contract value of $1,337.70. This non-set-aside, competitively awarded delivery order carries a firm fixed price structure and is scheduled for completion by September 15, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Vyvanse 20 mg capsules (100 count) with a contract ceiling value of $2,229.50. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 2, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract ceiling value of $1,773.46. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 26, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100-count units) on August 15, 2025, with a ceiling value of $4,198.84. This firm fixed-price delivery order is set to be completed by August 18, 2025, and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award was competitively awarded without set-aside designation and represents a child contract under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Vyvanse 10 mg capsules (100-count units) with a contract ceiling value of $1,333.84. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and carries no set-aside designation, indicating it was competitively awarded. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $14,662.29. This non-competitive delivery order is set to be completed by August 29, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract valued at $1,143.98. The delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a non-competitive award to the prime contractor. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 30 mg capsules (100-count) with a contract value of $2,117.56 and completion date of July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- SPE2DB22D2103Indefinite Delivery Contract
- SPE2DB22D2103-SPE2DB25FR9UNDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Vyvanse 10 mg capsules (100 count) under contract number 4569458763. The order, valued at $14,907.14, carries a firm fixed price and is scheduled for completion by September 15, 2025. This is a non-set-aside competitive award, reflecting AmerisourceBergen's capability to meet federal procurement requirements in open competition. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables AmerisourceBergen to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The Vyvanse order supports the Defense Health Agency and other federal healthcare systems as part of DLA's broader pharmaceutical supply mission, which encompasses specialty medications, brand-name and generic drugs, and vaccines across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.9k | 9/12/25 |